注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Erasca Inc是一家臨床階段精準腫瘤學公司。該公司專注於發現、開發和商業化針對RAS/MAPK通路驅動的癌症的療法。該公司從事腫瘤學和RAS靶向治療,以創建旨在全面關閉RAS/MAPK通路以治療癌症的療法和組合方案。該公司的主要候選產品是ERAS-007和ERAS-601,它們共同構成了其第一個MAPKlamp。ERAS-007被設計為ERK1/2的口服抑製劑,已在Asana完成的晚期實體瘤患者的I期臨床試驗中作為單一藥物進行了評估。ERAS-601是一種口服SHP2抑製劑,目前正在進行人體I期臨床試驗FLAGSHP-1。該公司的SHP2抑製劑旨在阻斷致癌信號轉導並延緩治療耐藥性的發生,這有可能成為針對RAS/MAPK通路改變的癌症的聯合治療的支柱。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Pratik S. Multani | 57 | 2018 | Independent Director |
Valerie Harding-Start | 64 | 2019 | Independent Director |
James A. Bristol | 77 | 2018 | Independent Director |
John Lo | - | 2022 | Senior Commercial Advisor & Member of Research, Development and Commercial Advisory Board |
Alexander Whitman Casdin | 56 | 2018 | Independent Director |
Julie Hambleton | 66 | 2021 | Independent Director |
Karen Cichowski | - | - | Scientific Advisory Board Member |
Pablo Rodriguez-Viciana | - | - | Scientific Advisory Board Member |
Bruce D. Roth | - | - | Member of R&D Advisory Board |
Linda Robertson | - | - | Member of R&D Advisory Board |
Kevan M. Shokat | - | - | Scientific Advisory Board Member |
Jonathan E. Lim | 52 | 2018 | Co-Founder, Chairman & CEO |
Gregory Cosma | - | - | Member of R&D Advisory Board |
David Matthews | 81 | - | Member of R&D Advisory Board |
Paul G. Pearson | 63 | - | Member of R&D Advisory Board |
James L. Freddo | 69 | - | Member of R&D Advisory Board |
Ryan B. Corcoran | - | - | Scientific Advisory Board Member |
George Daniel Demetri | 67 | - | Scientific Advisory Board Member |
Stephen C. Blacklow | - | - | Scientific Advisory Board Member |
Jane Chang | - | - | Member of R&D Advisory Board |
Jean I. Liu | 56 | 2022 | Independent Director |
Michael D. Varney | 66 | 2020 | Chairman of Research & Development, Scientific Advisory Board Member and Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核